BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 23044446)

  • 1. Outcomes of Category III DOTS treatment in immunocompetent patients with tuberculosis pleural effusion.
    Sharma SK; Solanki R; Mohan A; Jain NK; Chauhan LS;
    Int J Tuberc Lung Dis; 2012 Nov; 16(11):1505-9. PubMed ID: 23044446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intermittent tuberculosis treatment for patients with isoniazid intolerance or drug resistance.
    Reves R; Heilig CM; Tapy JM; Bozeman L; Kyle RP; Hamilton CD; Bock N; Narita M; Wing D; Hershfield E; Goldberg SV;
    Int J Tuberc Lung Dis; 2014 May; 18(5):571-80. PubMed ID: 24903795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of lymph node tuberculosis--a randomized clinical trial of two 6-month regimens.
    Jawahar MS; Rajaram K; Sivasubramanian S; Paramasivan CN; Chandrasekar K; Kamaludeen MN; Thirithuvathas AJ; Ananthalakshmi V; Prabhakar R
    Trop Med Int Health; 2005 Nov; 10(11):1090-8. PubMed ID: 16262733
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of a 6-month versus 9-month intermittent treatment regimen in HIV-infected patients with tuberculosis: a randomized clinical trial.
    Swaminathan S; Narendran G; Venkatesan P; Iliayas S; Santhanakrishnan R; Menon PA; Padmapriyadarsini C; Ramachandran R; Chinnaiyan P; Suhadev M; Sakthivel R; Narayanan PR
    Am J Respir Crit Care Med; 2010 Apr; 181(7):743-51. PubMed ID: 19965813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of a non-rifampicin continuation phase (6HE) following thrice-weekly intensive phase for the treatment of new sputum positive pulmonary tuberculosis.
    Indian J Tuberc; 2007 Apr; 54(2):84-90. PubMed ID: 17575680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low Serum Concentrations of Rifampicin and Pyrazinamide Associated with Poor Treatment Outcomes in Children with Tuberculosis Related to HIV Status.
    Ramachandran G; Kumar AK; Kannan T; Bhavani PK; Kumar SR; Gangadevi NP; Banurekha VV; Sudha V; Venkatesh S; Ravichandran N; Kalpana S; Mathevan G; Sanjeeva GN; Agarwal D; Swaminathan S
    Pediatr Infect Dis J; 2016 May; 35(5):530-4. PubMed ID: 26825153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Split-drug regimens for the treatment of patients with sputum smear-positive pulmonary tuberculosis--a unique approach.
    Santha T; Rehman F; Mitchison DA; Sarma GR; Reetha AM; Prabhaker R;
    Trop Med Int Health; 2004 May; 9(5):551-8. PubMed ID: 15117298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term efficacy of 6-month therapy with isoniazid and rifampin compared with isoniazid, rifampin, and pyrazinamide treatment for pleural tuberculosis.
    García-Rodríguez JF; Valcarce-Pardeiro N; Álvarez-Díaz H; Mariño-Callejo A
    Eur J Clin Microbiol Infect Dis; 2019 Nov; 38(11):2121-2126. PubMed ID: 31377953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Age, nutritional status and INH acetylator status affect pharmacokinetics of anti-tuberculosis drugs in children.
    Ramachandran G; Hemanth Kumar AK; Bhavani PK; Poorana Gangadevi N; Sekar L; Vijayasekaran D; Banu Rekha VV; Ramesh Kumar S; Ravichandran N; Mathevan G; Swaminathan S
    Int J Tuberc Lung Dis; 2013 Jun; 17(6):800-6. PubMed ID: 23676165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity.
    Sharma SK; Singla R; Sarda P; Mohan A; Makharia G; Jayaswal A; Sreenivas V; Singh S
    Clin Infect Dis; 2010 Mar; 50(6):833-9. PubMed ID: 20156055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse drug reactions observed during DOTS.
    Dhingra VK; Rajpal S; Aggarwal N; Aggarwaln JK; Shadab K; Jain SK
    J Commun Dis; 2004 Dec; 36(4):251-9. PubMed ID: 16506547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contralateral pleural effusion during chemotherapy for tuberculous pleural effusion.
    Puri MM; Arora VK
    Med J Malaysia; 2000 Sep; 55(3):382-4. PubMed ID: 11200723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of a combined preparation of isoniazid, rifampicin and pyrazinamide (Rifater) in the initial phase of chemotherapy in three 6-month regimens for smear-positive pulmonary tuberculosis: a five-year follow-up report.
    Teo SK
    Int J Tuberc Lung Dis; 1999 Feb; 3(2):126-32. PubMed ID: 10091877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long term follow up of HIV-infected patients with tuberculosis treated with 6-month intermittent short course chemotherapy.
    Swaminathan S; Deivanayagam CN; Rajasekaran S; Venkatesan P; Padmapriyadarsini C; Menon PA; Ponnuraja C; Dilip M
    Natl Med J India; 2008; 21(1):3-8. PubMed ID: 18472696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of thrice-weekly rifampicin, isoniazid and pyrazinamide in adult tuberculosis patients in India.
    Hemanth Kumar AK; Kannan T; Chandrasekaran V; Sudha V; Vijayakumar A; Ramesh K; Lavanya J; Swaminathan S; Ramachandran G
    Int J Tuberc Lung Dis; 2016 Sep; 20(9):1236-41. PubMed ID: 27510252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-course chemotherapy for tuberculous pleural effusion and culture-negative pulmonary tuberculosis.
    Ormerod LP; McCarthy OR; Rudd RM; Horsfield N
    Tuber Lung Dis; 1995 Feb; 76(1):25-7. PubMed ID: 7718842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tuberculous lymphadenopathy: a multicentre operational study of 6-month thrice weekly directly observed treatment.
    Jindal SK; Aggarwal AN; Gupta D; Ahmed Z; Gupta KB; Janmeja AK; Kashyap S; Singh M; Mohan A; Whig J
    Int J Tuberc Lung Dis; 2013 Feb; 17(2):234-9. PubMed ID: 23317960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of the 6-month thrice-weekly regimen in the treatment of new sputum smear-positive pulmonary tuberculosis under clinical trial conditions.
    Banu Rekha VV; Rajaram K; Kripasankar AS; Parthasarathy R; Umapathy KC; Sheikh I; Selvakumar N; Victor M; Niruparani C; Sridhar R; Jawahar MS
    Natl Med J India; 2012; 25(4):196-200. PubMed ID: 23278775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients].
    Wada M
    Kekkaku; 2001 Jan; 76(1):33-43. PubMed ID: 11211781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.